Drug intelligence / Profile preview

DW-1401

Development stage: Phase 3
Lead developer: Daewon Pharm
Modality: Small Molecules
Administration: Oral

Overview

DW-1401 is a small molecule drug developed by Daewon Pharmaceutical. It has been investigated for the treatment of digestive system disorders, specifically acute and chronic gastritis. The drug reached Phase 3 clinical trials, where its efficacy and safety were evaluated in comparison to Stillen (an established anti-gastritis medication) in patients diagnosed with acute or chronic gastritis confirmed by gastroscopy. The precise mechanism of action and molecular target for DW-1401 have not been disclosed in public sources[1][2][3][4].

Brand names: Escorten
Other names: Artemisia asiatica extractArtemisia asiatica extract 60mg

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on DW-1401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW-1401.

Explore the full profile